Know thy enemy: Why are tumor-infiltrating regulatory T cells so deleterious?

doi:10.4161/onci.19401

. 2012 Jul 1;1(4):575-577.

doi: 10.4161/onci.19401.

Know thy enemy: Why are tumor-infiltrating regulatory T cells so deleterious?

Andrea Facciabene¹, Stephen Santoro, George Coukos

Affiliations

PMID: 22754792
PMCID: PMC3382887
DOI: 10.4161/onci.19401

Know thy enemy: Why are tumor-infiltrating regulatory T cells so deleterious?

Andrea Facciabene et al. Oncoimmunology. 2012.

. 2012 Jul 1;1(4):575-577.

doi: 10.4161/onci.19401.

Authors

Andrea Facciabene¹, Stephen Santoro, George Coukos

Affiliation

¹ Ovarian Cancer Research Center; Perelman School of Medicine; University of Pennsylvania; Philadelphia, USA.

PMID: 22754792
PMCID: PMC3382887
DOI: 10.4161/onci.19401

Abstract

We recently described hypoxia as one of the leading mechanism for the recruitment of regulatory T cells (Treg) through CCL28 chemokine in ovarian cancer. Treg promote progression of cancer through tumor-specific immune paralysis but also reprogramming of angiogenesis. We review these mechanisms and discuss the challenges and opportunities for therapy targeting Treg.

PubMed Disclaimer

Figures

**Figure 1.**
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells: (A) Hypoxia upregulates CCL28 expression and recruit Treg (B) Once in the tumor Treg shut down the antitumor immune response and foster angiogenesis.

See this image and copyright information in PMC

Cited by

The metastasis-promoting roles of tumor-associated immune cells.
Smith HA, Kang Y. Smith HA, et al. J Mol Med (Berl). 2013 Apr;91(4):411-29. doi: 10.1007/s00109-013-1021-5. Epub 2013 Mar 21. J Mol Med (Berl). 2013. PMID: 23515621 Free PMC article. Review.
Regulatory T cells in the treatment of disease.
Sharabi A, Tsokos MG, Ding Y, Malek TR, Klatzmann D, Tsokos GC. Sharabi A, et al. Nat Rev Drug Discov. 2018 Nov;17(11):823-844. doi: 10.1038/nrd.2018.148. Epub 2018 Oct 12. Nat Rev Drug Discov. 2018. PMID: 30310234 Review.
IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell.
Shao L, Hou W, Scharping NE, Vendetti FP, Srivastava R, Roy CN, Menk AV, Wang Y, Chauvin JM, Karukonda P, Thorne SH, Hornung V, Zarour HM, Bakkenist CJ, Delgoffe GM, Sarkar SN. Shao L, et al. Cancer Immunol Res. 2019 Aug;7(8):1258-1266. doi: 10.1158/2326-6066.CIR-18-0711. Epub 2019 Jun 25. Cancer Immunol Res. 2019. PMID: 31239318 Free PMC article.
Tumor-infiltrating regulatory T cells: phenotype, role, mechanism of expansion in situ and clinical significance.
Tanchot C, Terme M, Pere H, Tran T, Benhamouda N, Strioga M, Banissi C, Galluzzi L, Kroemer G, Tartour E. Tanchot C, et al. Cancer Microenviron. 2013 Aug;6(2):147-57. doi: 10.1007/s12307-012-0122-y. Epub 2012 Oct 27. Cancer Microenviron. 2013. PMID: 23104434 Free PMC article.
Blood immune cell biomarkers in lung cancer.
Riemann D, Cwikowski M, Turzer S, Giese T, Grallert M, Schütte W, Seliger B. Riemann D, et al. Clin Exp Immunol. 2019 Feb;195(2):179-189. doi: 10.1111/cei.13219. Epub 2018 Nov 9. Clin Exp Immunol. 2019. PMID: 30246868 Free PMC article.

See all "Cited by" articles

References

1. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654–66. doi: 10.1056/NEJMoa051424. - DOI - PubMed
1. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203–13. doi: 10.1056/NEJMoa020177. - DOI - PubMed
1. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942–9. doi: 10.1038/nm1093. - DOI - PubMed
1. Yu P, Lee Y, Liu W, Krausz T, Chong A, Schreiber H, et al. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med. 2005;201:779–91. doi: 10.1084/jem.20041684. - DOI - PMC - PubMed
1. Buckner JH. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol. 2010;10:849–59. doi: 10.1038/nri2889. - DOI - PMC - PubMed

LinkOut - more resources

Full Text Sources

[1] Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654–66. doi: 10.1056/NEJMoa051424. - DOI - PubMed

[2] Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654–66. doi: 10.1056/NEJMoa051424. - DOI - PubMed

[3] Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203–13. doi: 10.1056/NEJMoa020177. - DOI - PubMed

[4] Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203–13. doi: 10.1056/NEJMoa020177. - DOI - PubMed

[5] Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942–9. doi: 10.1038/nm1093. - DOI - PubMed

[6] Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942–9. doi: 10.1038/nm1093. - DOI - PubMed

[7] Yu P, Lee Y, Liu W, Krausz T, Chong A, Schreiber H, et al. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med. 2005;201:779–91. doi: 10.1084/jem.20041684. - DOI - PMC - PubMed

[8] Yu P, Lee Y, Liu W, Krausz T, Chong A, Schreiber H, et al. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med. 2005;201:779–91. doi: 10.1084/jem.20041684. - DOI - PMC - PubMed

[9] Buckner JH. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol. 2010;10:849–59. doi: 10.1038/nri2889. - DOI - PMC - PubMed

[10] Buckner JH. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol. 2010;10:849–59. doi: 10.1038/nri2889. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Know thy enemy: Why are tumor-infiltrating regulatory T cells so deleterious?

Affiliation

Know thy enemy: Why are tumor-infiltrating regulatory T cells so deleterious?

Authors

Affiliation

Abstract

Figures

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources